Skip to main content
. 2013 Jul 2;139(4):533–544. doi: 10.1111/imm.12106

Figure 1.

Figure 1

Epstein–Barr virus (EBV)-specific T-cell responses determined by standard and cultured ELISPOT assays in healthy subjects. Peripheral blood mononuclear cells (PBMC) from EBV-seropositive (n = 20) and EBV-seronegative (n = 3) healthy subjects were evaluated in response to peptide pools (15 amino acids in length with an 11-amino-acid overlap) representing the full-length lytic (BZLF1 and BMRF1) and latent (EBNA1, EBNA3a, EBNA3b, EBNA3c, LMP1 and LMP2) EBV proteins. Results are shown as net spots/million PBMC for standard (a) and cultured (b) ELISPOT responses. EBV-specific T-cell responses determined by the cultured ELISPOT assay are significantly higher than those detected by the standard ELISPOT assay (P ≤ 0·002, two-tailed Wilcoxon signed rank test). Box and whisker plots (Tukey) indicate median (middle line in the box) EBV-specific T-cell responses detected in EBV-seropositive individuals. Data from each EBV-seronegative subject were plotted individually and the horizontal line marks the respective median number.